Antiproliferative Effects of Free and Encapsulated Hypericum Perforatum L. Extract and Its Potential Interaction with Doxorubicin for Esophageal Squamous Cell Carcinoma
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objectives: Esophageal squamous cell carcinoma (ESCC) is considered as a deadly medical condition that affects a growing number of people worldwide. Targeted therapy of ESCC has been suggested recently and required extensive research. With cyclin D1 as a therapeutic target, the present study aimed at evaluating the anticancer effects of doxorubicin (Dox) or Hypericum perforatum L. (HP) extract encapsulated in poly(lactic-co-glycolic acid) (PLGA) nanoparticles on the ESCC cell line KYSE30. Methods: Nanoparticles were prepared using double emulsion method. Cytotoxicity assay was carried out to measure the anti-proliferation activity of Dox-loaded (Dox NPs) and HP-loaded nanoparticles (HP NPs) against both cancer and normal cell lines. The mRNA gene expression of cyclin D1 was evaluated to validate the cytotoxicity studies at molecular level. Results: Free drugs and nanoparticles significantly inhibited KYSE30 cells by 55-73% and slightly affected normal cells up to 29%. The IC50 of Dox NPs and HP NPs was ~ 0.04-0.06 mg/mL and ~ 0.6-0.7 mg/mL, respectively. Significant decrease occurred in cyclin D1 expression by Dox NPs and HP NPs (P < 0.05). Exposure of KYSE-30 cells to combined treatments including both Dox and HP extract significantly increased the level of cyclin D1 expression as compared to those with individual treatments (P < 0.05). Conclusion: Dox NPs and HP NPs can successfully and specifically target ESCC cells through downregulation of cyclin D1. The simultaneous use of Dox and HP extract should be avoided for the treatment of ESCC.
Abstract
Objectives: Esophageal squamous cell carcinoma (ESCC) is considered as a deadly medical condition that affects a growing number of people worldwide. Targeted therapy of ESCC has been suggested recently and required extensive research. With cyclin D1 as a therapeutic target, the present study aimed at evaluating the anticancer effects of doxorubicin (Dox) or Hypericum perforatum L. (HP) extract encapsulated in poly(lactic-co-glycolic acid) (PLGA) nanoparticles on the ESCC cell line KYSE30. Methods: Nanoparticles were prepared using double emulsion method. Cytotoxicity assay was carried out to measure the anti-proliferation activity of Dox-loaded (Dox NPs) and HP-loaded nanoparticles (HP NPs) against both cancer and normal cell lines. The mRNA gene expression of cyclin D1 was evaluated to validate the cytotoxicity studies at molecular level. Results: Free drugs and nanoparticles significantly inhibited KYSE30 cells by 55-73% and slightly affected normal cells up to 29%. The IC50 of Dox NPs and HP NPs was ~ 0.04-0.06 mg/mL and ~ 0.6-0.7 mg/mL, respectively. Significant decrease occurred in cyclin D1 expression by Dox NPs and HP NPs (P < 0.05). Exposure of KYSE-30 cells to combined treatments including both Dox and HP extract significantly increased the level of cyclin D1 expression as compared to those with individual treatments (P < 0.05). Conclusion: Dox NPs and HP NPs can successfully and specifically target ESCC cells through downregulation of cyclin D1. The simultaneous use of Dox and HP extract should be avoided for the treatment of ESCC.
참고문헌 (48)
- Malek M, "Risk of cancer in diabetes : the effect of metformin", ISRN endocrinology, 2013, pp.636927~ (2013)
- Yadav AK, "Development and characterization of hyaluronic acid–anchored PLGA nanoparticulate carriers of doxo-rubicin", Nanomedicine : Nanotechnology, Biology and Medicine, 3(4), pp.246~257 (2007)
- Abbas G, "Overview of esophageal cancer", Annals of cardiothoracic surgery, 6(2), pp.131~136 (2017)
- Chen Z, "Incidence and survival differences in esophageal cancer among ethnic groups in the United States", Oncotarget, 8(29), pp.47037~47051 (2017)
- Rafiemanesh H, "The trend in histological changes and the incidence of esophagus cancer in Iran(2003-2008)", Int J Prev Med, 7(1), pp.31~ (2016)
- Enzinger PC, "Esophageal cancer", The New England journal of medicine, 349(23), pp.2241~2252 (2003)
- Phukan RK, "Betel nut and tobacco chewing; potential risk factors of cancer of oesophagus in Assam, India", British journal of cancer, 85(5), pp.661~667 (2001)
- Lin DC, "Protein alterations in ESCC and clinical implications: a review. Diseases of the esophagus", official journal of the International Society for Diseases of the Esophagus, 22(1), pp.9~20 (2009)
- Chidambaram M, "Nanotherapeutics to overcome conventional cancer chemotherapy limitations", Journal of pharmacy & pharmaceutical sciences, 14(1), pp.67~77 (2011)
- Chouhan R, "Real time in vitro studies of doxorubicin release from PHEMA nanoparticles", Journal of nanobiotechnology, 7(1), pp.5~ (2009)
- Bromberg L, "Effects of polyether-modified poly(acrylic acid)microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers", Journal of controlled release, 88(1), pp.11~22 (2003)
- Gupta RB, "Nanoparticle Technology for Drug Delivery" (2006), Taylor and Francic
- Amjadi I, "Nanoencapsulation of Hypericum perforatum and doxorubicin anticancer agents in PLGA nanoparticles through double emulsion technique", Micro & Nano Letters, 8(5), pp.243~247 (2013)
- Bonakdar S, "Effect of Freezing and Thawing Process on Betamethasone Acetate Release from Polyvinyl alcohol Nanospheres", Solid State Phenomena, 151, pp.159~165 (2009)
- Lebold T, "Nanostructured silica materials as drug-delivery systems for doxorubicin : single molecule and cellular studies", Nano letters, 9(8), pp.2877~2883 (2009)
- Wong HL, "A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system", Journal of Pharmacology and Experimental Therapeutics, 317(3), pp.1372~1381 (2006)
- Yu D, "Dialdehyde starch nanoparticles : Preparation and application in drug carrier", Chinese Science Bulletin, 52(21), pp.2913~2918 (2007)
- Mohajeri M, "Protective effects of curcumin against doxorubicin-induced toxicity and resistance : A review", Critical Reviews in Oncology, 2018, pp.122, 30~51
- Soleymani S, "Clinical risks of St John’s Wort(Hypericum perforatum)co-administration", Expert opinion on drug metabolism & toxicology, 13(10), pp.1047~1062 (2017)
- Klemow KM, "Herbal Medicine: Biomolecular and Clinical Aspects", pp.2011, CRC Press
- Dost T, "The effect of Hypericum perforatum (St. John's Wort) on experimental colitis in rat", Dig Dis Sci, 54(6), pp.1214~1221 (2009)
- Cayci MK, "Hypericum perforatum extracts healed gastric lesions induced by hypothermic restraint stress in Wistar rats", Saudi Med J, 30(6), pp.750~754 (2009)
- Zdunic G, "Evaluation of Hypericum perforatum oil extracts for an antiinflammatory and gastroprotective activity in rats", Phytother Res, 23(11), pp.1559~1564 (2009)
- Karaarslan S, "Does St. John’s Wort cause regression in gastrointestinal system adenocarcinomas?", World Journal of Gastrointestinal Oncology, 7(11), pp.369~374 (2015)
- Amjadi I, "Anticancer activity of nanoparticles based on PLGA and its co-polymer : in-vitro evaluation", Iranian journal of pharmaceutical research : IJPR, 12(4), pp.623~634 (2013)
- Takemura G, "Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management", Prog Cardiovasc Dis, 49(5), pp.330~352 (2007)
- Cox J, "Mechanisms of doxorubicin resistance in hepatocellular carcinoma", Hepatic oncology, 3(1), pp.57~59 (2016)
- Zhou S, "Pharmacokinetic interactions of drugs with St John’s wort", Journal of Psychopharmacology, 18(2), pp.262~276 (2004)
- Bhadra R, "Herb-drug interaction : The importance of communicating with primary care physicians", The Australasian medical journal, 8(10), pp.315~319 (2015)
- Mannel M, "Drug interactions with St John’s wort", Drug safety, 27(11), pp.773~797 (2004)
- Saddiqe Z, "A review of the antibacterial activity of Hypericum perforatum L", Journal of ethnopharmacology, 131(3), pp.511~521 (2010)
- Öztürk N, "Wound-healing activity of St. John's Wort (Hypericum perforatum L.) on chicken embryonic fibroblasts", Journal of ethnopharmacology, 111(1), pp.33~39 (2007)
- Husain GM, "Hypolipidemic and antiobesity-like activity of standardised extract of Hypericum perforatum L. in rats", ISRN pharmacology, 2011, pp.505247~ (2011)
- Feily A, "The inhibitory effect of Hypericum perforatum extract on morphine withdrawal syndrome in rat and comparison with clonidine", Phytotherapy research, 23(11), pp.1549~1552 (2009)
- Davids LM, "Hypericin phototoxicity induces different modes of cell death in melanoma and human skin cells", Journal of Photochemistry and Photobiology B: Biology, 91(2-3), pp.67~76 (2008)
- Zou YP, "Protective effects of a flavonoid- rich extract of Hypericum perforatum L. against hydrogen peroxide-induced apoptosis in PC12 cells", Phytotherapy research, 24(S1), pp.S6~S10 (2010)
- Van Strater AC, "Interaction of St John's wort(Hypericum perforatum)with clozapine", Int Clin Psychopharmacol, 27(2), pp.121~124 (2012)
- Borrelli F, "Herb–drug interactions with St John’s wort(Hypericum perforatum) : an update on clinical observations", The AAPS journal, 11(4), pp.710~727 (2009)
- Lee HH, "Combination treatment with paclitaxel and doxorubicin inhibits growth of human esophageal squamous cancer cells by inactivation of Akt", Oncology reports, 31(1), pp.183~188 (2014)
- Asakura T, "Glutathione-doxorubicin conjugate expresses potent cytotoxicity by suppression of glutathione S-transferase activity : comparison between doxorubicin-sensitive and-resistant rat hepatoma cells", British journal of cancer, 76(10), pp.1333~ (1997)
- Clementi ME, "Doxorubicin-derived metabolites induce release of cytochrome C and inhibition of respiration on cardiac isolated mitochondria", Anticancer research, 23(3B), pp.2445~2450 (2003)
- Marchand DJ, "Depression of cytochrome P-450-dependent drug biotransformation by adriamycin", Toxicology and applied pharmacology, 58(1), pp.83~88 (1981)
- Shibayama Y, "John's Wort(Hypericum perforatum)induces overexpression of multidrug resistance protein 2(MRP2)in rats : a 30-day ingestion study", Food Chem Toxicol, 42(6), pp.995~1002 (2004)
- Smith PF, "Induction of imatinib metabolism by hypericum perforatum", Blood, 104(4), pp.1229~1230 (2004)
- Frye RF, "Effect of St John's wort on imatinib mesylate pharmacokinetics", Clinical Pharmacology & Therapeutics, 76(4), pp.323~329 (2004)
- Mathijssen RH, "Effects of St. John's wort on irinotecan metabolism", Journal of the National Cancer Institute, 94(16), pp.1247~1249 (2002)
- Goey AK, "The effect of St John’s wort on the pharmacokinetics of docetaxel", Clinical pharmacokinetics, 53(1), pp.103~110 (2014)
- Spratlin J, "Pharmacogenetics of paclitaxel metabolism", Critical Reviews in Oncology, 2007, pp.61(3), 222~229